Gilead Sciences, Inc. (GILD) Stock Analysis
Temp Headwind edge
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $125.59, but acceptable to hold if already in. Reason: Negative momentum.
Gilead Sciences is a biopharmaceutical company focused on HIV, liver diseases (hepatitis B/C), hematology/oncology, and inflammatory diseases. It earns revenue primarily through sales of branded antiviral therapies (Biktarvy, Veklury, Trodelvy) distributed via a concentrated... Read more
Hold if already holding. Not a fresh buy at $125.59, but acceptable to hold if already in. Reason: Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 55d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and news soft fda negative. Suitability: conservative.
Recent developments
updated 2026-06-12Recent Developments — Gilead Sciences, Inc.
Latest news
- NEWS Gilead Sciences (NASDAQ:GILD) CEO Sells $1,291,600.00 in Stock - MarketBeat — MarketBeat negative
- NEWS Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade - Stock Titan — Stock Titan negative
- NEWS Assessing Whether Gilead Sciences (GILD) Looks Undervalued After Recent Share Price Performance - simplywall.st — simplywall.st positive
- NEWS Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat — MarketBeat positive
- NEWS GILD Upgraded by Maxim Group -- Price Target Announced at $165 - GuruFocus — GuruFocus positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $125.59, but acceptable to hold if already in. Reason: Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $142.04 (+13.1%), stop $118.20 (−6.3%), A.R:R 2.2:1. Score 6.1/10, moderate confidence.
Take-profit target: $142.04 (+13.1% upside). Target $142.04 (+13.1%), stop $118.20 (−6.3%), A.R:R 2.2:1. Stop-loss: $118.20.
Negative momentum.
Gilead Sciences, Inc. trades at a P/E of 17.1 (forward 13.1). TrendMatrix value score: 6.3/10. Verdict: Hold.
39 analysts cover GILD with a consensus score of 4.1/5. Average price target: $158.
What does Gilead Sciences, Inc. do?Gilead Sciences is a biopharmaceutical company focused on HIV, liver diseases (hepatitis B/C), hematology/oncology, and...
Gilead Sciences is a biopharmaceutical company focused on HIV, liver diseases (hepatitis B/C), hematology/oncology, and inflammatory diseases. It earns revenue primarily through sales of branded antiviral therapies (Biktarvy, Veklury, Trodelvy) distributed via a concentrated wholesale channel in the U.S. and internationally.